The Biostatistics Core will provide statistical support for the research conducted in the Glioma SPORE program, including related database and computing requirements. The Core will provide consultation and expertise on the development and implementation of plans for data collection, particularly the coding convention and variable format required for statistical analysis. The Core will contribute to the data management plan, including form design and database requirements, during development of the SPORE-related clinical trials. The Core will provide expertise and resources for data transfer, merging, sharing and security while maintaining the confidentiality of all patient-related protected health information. The Core will provide ready and dedicated access to statistical expertise for the design, planning and conduct of preclinical experiments, clinical trials and correlative tissue and biomarker studies. Analysis of the clinical trials will include interim monitoring, if necessary, including the stopping rules for safety and futility. The Core will also provide statistical expertise for data analysis and interpretation of research studies, including manuscript preparation.
The Biotatistics Core is critical to this research program in order to ensure that the proposed studies will satisfy the prevailing and emerging scientific standards for statistical rigor. Successful translation of the preclinical and clinical studies to patient care can be accomplished only ifthe studies were statistically valid in terms of experimental design, data analysis and overall interpretation.
|Zhao, Yingchao; Liu, Pinan; Zhang, Na et al. (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115:E2077-E2084|
|Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351|
|McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25|
|McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804|
|Shankar, Ganesh M; Kirtane, Ameya R; Miller, Julie J et al. (2018) Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A 115:E8388-E8394|
|Arvanitis, Costas D; Askoxylakis, Vasileios; Guo, Yutong et al. (2018) Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci U S A 115:E8717-E8726|
|Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71|
|Nowosielski, Martha; Wen, Patrick Y (2018) Imaging Criteria in Neuro-oncology. Semin Neurol 38:24-31|
|Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332|
|Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20|
Showing the most recent 10 out of 84 publications